The phase 3 WSG-ADAPT HR+/HER2- trial presented first efficacy results in patients with luminal early breast cancer in 2020, showing that endocrine therapy (ET) alone produced excellent outcomes for those with intermediate genomic risk and decreased tumor cell proliferation. At the 2021 ASCO Annual Meeting, results for high-risk patients were presented, showing that ET alone was effective for patients with up to 3 positive lymph nodes and low recurrence scores. Patients with higher recurrence scores or additional risk factors were assigned to chemotherapy plus ET. The primary endpoint was invasive disease-free survival, with secondary endpoints including distant disease-free survival and overall survival.
Source link
On-Treatment Ki-67: A Promising Prognostic Marker for Early Breast Cancer Management
